AirSculpt Technologies reported Q4 2025 revenue of $33.4 million, down about 15% year over year, with GAAP EPS of approximately -0.02, which beat consensus forecasts. Full-year 2025 revenue fell to $151.8 million with a net loss of $11.7 million. Shares recently traded near $3.17, reflecting volatile after-hours movement following the release.
About AirSculpt Technologies
AirSculpt Technologies, Inc. (NASDAQ: AIRS) is a national provider of premium body contouring procedures, specializing in minimally invasive fat removal and body sculpting services delivered under the Elite Body Sculpture brand.
The company is headquartered in Miami Beach, Florida, and operates a network of aesthetic centers across the United States and select international markets. AirSculpt focuses on high-end, cash-pay procedures, which exposes it to consumer discretionary trends and broader macroeconomic conditions.
AirSculpt’s recent fundamentals reflect a small-cap profile with a market capitalization of about $170 million and negative trailing EPS of roughly -0.30, implying a P/E ratio near -9.4. The company’s gross margin remains comparatively high for a healthcare services provider, with external data suggesting margins near the mid-60% range. AirSculpt does not currently pay a dividend, instead prioritizing reinvestment and balance sheet management as it navigates lower volumes and cost optimization initiatives.
Top Financial Highlights
- Q4 2025 revenue declined 14.6% year over year to $33.4 million from $39.2 million in Q4 2024.
- Full-year 2025 revenue fell 15.8% to $151.8 million compared with $180.4 million in 2024.
- Q4 2025 GAAP EPS was approximately -0.02, which beat the analyst forecast by just over 30%.
- Full-year 2025 GAAP EPS was about -0.19, below consensus expectations of roughly -0.10.
- Q4 2025 net loss narrowed to about $1.3 million, versus a loss of $5.0 million in the prior-year quarter.
- Full-year 2025 net loss widened to $11.7 million, compared with $8.0 million in full-year 2024.
- Q4 2025 gross margin was about 59%, representing roughly 2% points of expansion versus Q4 2024.
- Q4 2025 adjusted EBITDA was $2.5 million, up from $1.9 million a year earlier, with margin improving to roughly 7.4% of revenue.
- Full-year 2025 adjusted EBITDA totaled $15.1 million, down from $21.0 million in 2024, with margin near 10%.
- Q4 2025 operating cash flow used approximately $2.5 million, compared with $2.7 million provided in Q4 2024.
- Full-year 2025 operating cash flow was $3.1 million, down from $11.4 million in 2024, reflecting weaker volumes and higher one-time costs.
- Case volume in Q4 2025 fell about 15% to 2,604 from 3,064 in the year-ago quarter, while full-year cases declined 15.6% to 11,852.
- As of December 31, 2025, cash on hand was $8.4 million, with gross debt near $56 million; subsequent at-the-market (ATM) equity activity raised $14.8 million and reduced debt to roughly $45 million.
- 2026 guidance calls for revenue of about $151-$157 million and adjusted EBITDA of $15-$17 million, implying stable to modestly improved profitability despite flat topline expectations.
- Management highlighted a sequential improvement in same-store sales in Q4 relative to the first nine months of 2025, even as full-year same-store revenue remained under pressure.
AirSculpt Technologies, Inc. and Subsidiaries
Beat or Miss?
| Metric | Reported | Difference/Analysis |
| Q4 2025 Revenue | $33.4 million | Down about 15% year over year; no explicit consensus figure disclosed, suggesting a topline miss vs. underlying trends. |
| Q4 2025 GAAP EPS | -0.02 | Beat the forecast by roughly 30%, indicating better-than-expected cost control and margin performance. |
| FY 2025 GAAP EPS | -0.19 | Below consensus of about -0.10, reflecting full-year volume headwinds and one-time charges. |
| FY 2025 Revenue | $151.8 million | Near updated outlook of approximately $153 million; in line with reduced guidance issued earlier in 2025. |
What Leadership Is Saying?
“In the fourth quarter, we delivered sequential improvement in same-store sales versus the first nine months of the year and adjusted EBITDA ahead of the prior-year period. During 2025, we took significant steps to enhance our business approach and team, adding talent, improving business processes, implementing a new go-to-market strategy, and adding new procedures that expanded our market potential.”– Yogi Jashnani, CEO
“Our Q4 results reflect disciplined cost management and early benefits from our operational initiatives, with gross margin expanding and SG&A declining double digits year over year. While full-year cash generation was below prior-year levels, we believe our 2026 guidance balances prudent expense control with targeted investments to support sustainable profitability.”– CFO, earnings call commentary
Historical Performance
| Category | Q4 2025 | Q4 2024 | Change (%) |
| Revenue | $33.4 million | $39.2 million | Approximately -14.6% year over year. |
| Net Income (Loss) | – $1.3 million | – $5.0 million | Loss narrowed by about 74%, reflecting improved cost structure. |
| Operating Cash Flow | – $2.5 million | + $2.7 million | Swing of roughly -$5.2 million, indicating weaker cash conversion. |
Historical Performance of Peers (Illustrative)
Direct, pure-play public peers with identical business models are limited, so investors often benchmark AirSculpt against broader aesthetic or outpatient procedure companies and small-cap healthcare services providers. The figures below use representative small-cap aesthetics/healthcare services peers with similar revenue scale and margin profiles as an illustrative comparison of year-over-year trends rather than exact company matches.
| Category | AirSculpt FY 2025 g | Peer Group Median FY 2025* | Change vs. FY 2024 (AIRS) |
| Revenue | $151.8 million | ~$150–$200 million | About -15.8% for AirSculpt; peers generally showed low- to mid-single digit declines or modest growth. |
| Net Income (Loss) | – $11.7 million | Near breakeven to modest profit | Loss widened for AirSculpt vs. 2024, while many peers maintained relatively stable earnings. |
| Operating Margin | Approximately 10% adjusted EBITDA margin | High single-digit to low double-digit adjusted margins | Margin compressed for AirSculpt year over year, broadly in line with pressure seen across elective procedure providers. |
How the Market Reacted?
Following the Q4 and full-year 2025 release, AirSculpt shares have traded with elevated volatility, recently closing around $3.17, up more than 16% on a single trading day as investors digested the mixed update.
The market appears encouraged by the Q4 EPS beat, gross margin expansion, and reduced quarterly loss, even as full-year revenue and cash flow trends remain under pressure. Sentiment skews cautiously constructive, with guidance signaling stabilization and modest profitability improvements rather than a rapid rebound in volumes.
